Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 2016
| Autor: | Miriam Heinig, Ulrike Haug, Malte Braitmaier |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Epidemiology Hormone Replacement Therapy medicine.medical_treatment Hormone therapy Drug utilization Breast cancer Germany Hormone replacement therapy Menopause 030226 pharmacology & pharmacy Vaginal estrogen 03 medical and health sciences Route of administration 0302 clinical medicine Internal medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine Medical prescription Aged business.industry Cumulative dose Estrogen Replacement Therapy Hormone replacement therapy (menopause) Middle Aged medicine.disease Cross-Sectional Studies Women's Health Female business |
| Zdroj: | Pharmacoepidemiology and drug safety, 30(4):462-471 |
| Popis: | BACKGROUND: Prescribing of menopausal hormone therapy (MHT) declined drastically after publication of the Women's Health Initiative's (WHI) findings in 2002, but studies on longer-term trends and details of use are scarce. METHODS: We used the German Pharmacoepidemiological Research Database (GePaRD) containing health insurance claims data from ~25 million persons. Using data from 2004–2016, we conducted cross-sectional analyses to determine the prevalence of MHT use overall and by type and route of administration in women aged 45–75. In longitudinal analyses, we assessed MHT use over 5 years and compared the patterns between different time periods. RESULTS: From 2004 to 2016, prevalence of systemic MHT prescriptions decreased by >60% in women aged 55–65 and by >50% in women aged 50 and 70 years old. Prevalence declined for most types and routes of administration at all ages (−16% to −79%) with some exceptions, for example, local MHT (vaginal estrogen). Among 50-year-old women in 2012, 6% were already prescribed systemic MHT at age 49 and of the remaining women, 16% were newly prescribed systemic MHT before age 55. At all ages, the cumulative dose of systemic MHT prescribed over 5 years was lower in the period 2012–2016 compared to 2005–2009 (−6% to −46%). CONCLUSION: For most types of MHT and all age groups, prevalence declined considerably between 2004 and 2016 in Germany. The cumulative dose per MHT user also decreased, suggesting a trend towards a shorter duration of use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|